Kalpit Patel
Stock Analyst at B. Riley Securities
(1.08)
# 3,455
Out of 4,829 analysts
54
Total ratings
30%
Success rate
-11.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCYC Bicycle Therapeutics | Maintains: Neutral | $17 → $14 | $8.34 | +67.87% | 7 | May 2, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $37 | $20.15 | +83.62% | 1 | Mar 20, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $24 | $18.75 | +28.00% | 6 | Mar 5, 2025 | |
| GERN Geron | Maintains: Buy | $5.5 → $3.5 | $1.18 | +196.61% | 3 | Feb 18, 2025 | |
| VSTM Verastem | Maintains: Buy | $7 → $9 | $7.17 | +25.52% | 4 | Jan 31, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $10 | $4.20 | +138.10% | 1 | Jan 30, 2025 | |
| PDSB PDS Biotechnology | Maintains: Buy | $9 → $7 | $1.20 | +483.33% | 5 | Nov 25, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $85 → $40 | $6.45 | +520.16% | 2 | Sep 20, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Neutral | $31 → $36 | $30.07 | +19.72% | 2 | Jul 9, 2024 | |
| OVID Ovid Therapeutics | Maintains: Buy | $9 → $3 | $0.29 | +934.13% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $12.39 | +61.42% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $3.37 | +790.21% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $6.88 | -12.79% | 5 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $10.70 | +236.45% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $9 → $3 | $0.16 | +1,805.97% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $1.16 | +1,451.72% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $2.15 | +132.56% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $7.03 | +1,322.48% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $6.29 | +1,092.37% | 2 | Sep 3, 2021 |
Bicycle Therapeutics
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $8.34
Upside: +67.87%
ArriVent BioPharma
Mar 20, 2025
Initiates: Buy
Price Target: $37
Current: $20.15
Upside: +83.62%
Rigel Pharmaceuticals
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $18.75
Upside: +28.00%
Geron
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.18
Upside: +196.61%
Verastem
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $7.17
Upside: +25.52%
Foghorn Therapeutics
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $4.20
Upside: +138.10%
PDS Biotechnology
Nov 25, 2024
Maintains: Buy
Price Target: $9 → $7
Current: $1.20
Upside: +483.33%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $6.45
Upside: +520.16%
Kymera Therapeutics
Jul 9, 2024
Maintains: Neutral
Price Target: $31 → $36
Current: $30.07
Upside: +19.72%
Ovid Therapeutics
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $0.29
Upside: +934.13%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $12.39
Upside: +61.42%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $3.37
Upside: +790.21%
Sep 7, 2023
Reiterates: Buy
Price Target: $6
Current: $6.88
Upside: -12.79%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $10.70
Upside: +236.45%
Nov 11, 2022
Downgrades: Neutral
Price Target: $9 → $3
Current: $0.16
Upside: +1,805.97%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $1.16
Upside: +1,451.72%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $2.15
Upside: +132.56%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $7.03
Upside: +1,322.48%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $6.29
Upside: +1,092.37%